IT-141 (Etoposide IVECT™)
Advanced Solid Tumors
Phase 1Active
Key Facts
About Intezyne
Intezyne is a private, clinical-stage biotech company pioneering novel nanoparticle delivery platforms for oncology. Its lead technology, the IVECT™ method, enables the encapsulation and targeted delivery of highly potent but traditionally untreatable cytotoxic payloads. The company is advancing a pipeline of novel therapeutics, with its lead candidate, IT-141, having progressed into clinical trials. Intezyne represents a specialized player in the drug delivery and nanomedicine space, seeking to address significant unmet needs in cancer treatment.
View full company profileTherapeutic Areas
Other Advanced Solid Tumors Drugs
| Drug | Company | Phase |
|---|---|---|
| NT219 | Purple Biotech | Phase 1/2 |
| INDP-101 | Indaptus Therapeutics | Phase 1 |
| NST-101 (estimated) | Novastage Pharmaceuticals | Phase 1/2 |
| Meta10-TILs | Leman Biotech | Phase 1 |
| PM14 | PharmaMar | Phase 1/2 |
| Ecubectedin (PM54) | PharmaMar | Phase 1 |
| M8891 | Merck KGaA | Phase 1/2 |
| P-002 | Panacea Biotec | Phase 1/2 |
| Undisclosed kinase inhibitor | Tyligand Bioscience | Phase 1 |
| TYK-001 | TYK Medicines | Phase 1/2 |
| PT-112 | SciClone Pharmaceuticals | Phase 1 |
| AP-202 | Advance Pharmaceutical | Phase 1/2 |